| <P style="MARGIN: 0cm 0cm 0pt; TEXT-INDENT: 24pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-line-height-alt: 0pt; mso-char-indent-count: 2.0" align=left><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">美国</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">FDA</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">于</SPAN> <SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">5</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">月</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">13</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">日</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">批准默克公司的丙型肝炎药物伯赛匹<SPAN style="COLOR: black">韦（</SPAN></SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">boceprevir</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">），其商品名为</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">Victrelis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">Victrelis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">适用于慢性丙型肝炎成人患者，他们仍有一些肝功能，无论先前做过或未曾作过药物治疗。</SPAN> <SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial"><SPAN><SPAN lang=EN-US XML:LANG="EN-US"><FONT face=Arial>Victrelis</FONT></SPAN></SPAN></SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">获准与聚乙二醇</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">α-</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">干扰素（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">peginterferon alfa</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">）和利巴韦林（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; FONT-FAMILY: Arial; mso-font-kerning: 0pt" XML:LANG="EN-US">ribavirin</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">）联用。</SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt; TEXT-INDENT: 24pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-line-height-alt: 0pt; mso-char-indent-count: 2.0" align=left><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">在有</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">1500</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">名患者参与的两项</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">III</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">期临床试验中对</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">Victrelis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">的安全性和效果进行了评估。在这两项试验中，与现行的标准治疗方案即只使用聚乙二醇干扰素和利巴韦林相比，接受聚乙二醇干扰素和利巴韦林与</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">Victrelis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">联用方案组疗效明显提高，有</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">2/3</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者保持病毒学应答（即在停止治疗后</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: Arial" XML:LANG="EN-US">24</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">周血检丙型肝炎病毒已检测不出）。<SPAN>当患者完成治疗后保持病毒学应答，就表明丙型肝炎病毒感染已被治愈。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt; TEXT-INDENT: 24pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-line-height-alt: 0pt; mso-char-indent-count: 2.0" align=left><SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; FONT-FAMILY: 宋体; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">持续病毒学应答可使肝硬化、肝病并发症减少发生，降低肝癌发病率率，降低死亡率。</SPAN></SPAN></P> |
